Tempus AI, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric Lefkofsky
- Full Time Employees
- 3,800
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 600 West Chicago Avenue Chicago IL United States of America 60654
- IPO Date
- Jun 14, 2024
- CIK
- 0001717115
- Website
- tempus.com
- Similar Companies
- Business
- Tempus AI, Inc. operates as an innovative healthcare technology firm, dedicated to transforming patient care through the application of artificial intelligence. The company specializes in delivering comprehensive genomic sequencing diagnostics, including next-generation sequencing, polymerase chain reaction profiling, and advanced molecular pathology testing to a broad spectrum of healthcare entities. These clients include medical providers, pharmaceutical manufacturers, biotechnology innovators, and research institutions. The organization provides a suite of advanced platforms such as Tempus Lens, designed for scientists to explore, access, and analyze de-identified clinical, molecular, and imaging data, and Tempus Hub, a streamlined desktop and mobile interface for managing test orders and patient results. Their offerings also encompass predictive algorithmic tests, like Algos and Next, tailored for oncology and other therapeutic areas, as well as Trials, a service that facilitates patient matching for clinical studies. Tempus AI generates revenue primarily through its genomic testing services, data licensing, and clinical trial solutions. The company notably expanded its reach by going public on Nasdaq in June 2024 under the ticker TEM. Recent strategic developments include the November 2024 acquisition of Ambry Genetics, a $600 million deal, and the formation of SB Tempus, an AI healthcare joint venture in Japan with SoftBank. In April 2025, Tempus AI, AstraZeneca, and Pathos AI announced multi-year agreements, including $200 million in data licensing and model development fees to Tempus, to co-develop a significant multimodal foundation model in oncology, building on an earlier 2021 partnership. Further collaborations in 2025 include a partnership with Illumina for genomic testing integration and research alliances with Northwestern University for Alzheimer's disease and the Institute for Follicular Lymphoma Innovation. Headquartered in Chicago, Illinois, Tempus AI was established in 2015 and remains at the forefront of leveraging large-scale multimodal data and AI to accelerate precision medicine, with a significant presence among U.S. oncologists and top biopharma companies.
Tempus AI: The Data Flywheel Has Started Spinning
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead
Is Tempus AI Worth Buying as Growth Improves but Valuation Stays High?
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)
Tempus Q2 Earnings Call Highlights Data Growth and Pricing Upside
CellCarta Adds Tempus to CDx Commercialization Lab Network
Tempus Study Published in Nature Medicine Demonstrates Best-in-Class Performance of PRISM2 Across Diagnostic and Prognostic Applications
PERSONALIS SHAREHOLDER ALERT: PSNL Shareholders Interested in Pursuing Potential Claims Should Contact Julie & Holleman Regarding Proposed Sale to Tempus
Tempus AI Stock Slides Friday: What's Driving the Post-Earnings Reset?
TEM Q2 Loss Narrower Than Expected, Revenues Beat, Stock Up
Is Tempus AI Stock a Buy After Its CEO Sold 250,000 Shares?
Tempus AI, Inc. (TEM) Q2 2026 Earnings Call Transcript
Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics
Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates
Why Nancy Pelosi-Owned Tempus AI Stock Is Down After Q2 Earnings
Tempus Reports Second Quarter 2026 Results
3 Powerful AI Stocks Poised for the Next Massive Shift
Tempus AI Stock Before Q2 Earnings Release: To Buy, Hold or Sell?
A Small AI Company Just Took the Stage at One of the Biggest Events in Computing, and It Points to Where Drug Discovery Is Headed